{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-051964","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2026-08-03T21:15:26+00:00","discovered_at":"2026-08-03T21:16:00.765810+00:00","generated_at":"2026-08-03T21:16:08.544326+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Repligen CEO sends video to BioLife employees; merger expected to close in Q4 2026","bullets":["Repligen CEO Olivier Loeillot recorded video message for BioLife employees on August 3, 2026.","Merger still requires regulatory and shareholder approvals; expected close in Q4 2026.","Repligen describes itself as a bioprocessing tools company with ~2,000 employees globally.","BioLife's CryoStor platform supports majority of US cell-based therapy trials.","Until close, BioLife and Repligen will operate as separate independent companies."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-051964","json":"https://secwatch.observer/filing/0001628280-26-051964.json","markdown":"https://secwatch.observer/filing/0001628280-26-051964.md","text":"https://secwatch.observer/filing/0001628280-26-051964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828026051964/0001628280-26-051964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828026051964/blfs-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T21:16:08.544326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}